These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29236294)

  • 1. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
    Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
    Tallman MS; Gray R; Bennett JM; Variakojis D; Robert N; Wood WC; Rowe JM; Wiernik PH
    J Clin Oncol; 1995 Jul; 13(7):1557-63. PubMed ID: 7602344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
    Smith RE; Bryant J; DeCillis A; Anderson S;
    J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
    Lee JW; Oh H; You JY; Lee ES; Lee JH; Song SE; Lee NK; Jung SP; An JS; Cho KR; Kim CY; Park KH
    Eur J Cancer; 2023 Sep; 191():112952. PubMed ID: 37473463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
    Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
    J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
    Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
    JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
    Kaplan HG; Malmgren JA; Atwood MK
    BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
    Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
    Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
    Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
    Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
    Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin.
    Cremin P; Flattery M; McCann SR; Daly PA
    Ann Oncol; 1996 Sep; 7(7):745-6. PubMed ID: 8905034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.